Finally, NK CAR cells targeting different AML cell antigens (CD70, CD33, and FLT3, CLL-1) exhibit potent anti-leukemic effects “in vitro” for their powerful cytotoxic effects with limited off-target side effects and unique recognition mechanism [163,164,165] and are at present in preclinical evaluation. This evidence concerns the gene FLT3 and acute myeloid leukemia.